AE, count | Brazikumab/ Brazikumab (n = 52) | Placebo/ Brazikumab (n = 52) | Total (N = 104) |
---|---|---|---|
Total infectionsa | 42 | 58 | 100 |
Urinary tract infection | 4 | 5 | 9 |
Vulvovaginal mycotic infection | 1 | 6 | 7 |
Sinusitis | 1 | 6 | 7 |
Bronchitis | 2 | 4 | 6 |
Upper respiratory tract infection | 2 | 4 | 6 |
Tonsilitis | 2 | 3 | 5 |
Tooth infection | 3 | 2 | 5 |
Subcutaneous abscess | 4 | 0 | 4 |
Clostridium difficile colitis | 3 | 0 | 3 |
Pharyngitis streptococcal | 1 | 2 | 3 |
Anal abscess | 2 | 0 | 2 |
Anal candidiasis | 0 | 2 | 2 |
Ear infection | 0 | 2 | 2 |
Groin abscess | 1 | 1 | 2 |
Influenza | 1 | 1 | 2 |
Nasopharyngitis | 1 | 1 | 2 |
Pharyngitis | 2 | 0 | 2 |
Pyelonephritis | 1 | 1 | 2 |
Tooth abscess | 0 | 2 | 2 |